Compare BOW & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOW | CGEM |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.3M | 780.4M |
| IPO Year | 2024 | 2020 |
| Metric | BOW | CGEM |
|---|---|---|
| Price | $25.70 | $15.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $34.29 | $28.80 |
| AVG Volume (30 Days) | 217.4K | ★ 770.4K |
| Earning Date | 05-25-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.26 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $551,589,000.00 | N/A |
| Revenue This Year | $12.33 | N/A |
| Revenue Next Year | $17.20 | N/A |
| P/E Ratio | $16.07 | ★ N/A |
| Revenue Growth | ★ 29.58 | N/A |
| 52 Week Low | $22.15 | $5.68 |
| 52 Week High | $42.29 | $16.74 |
| Indicator | BOW | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 76.32 |
| Support Level | $23.72 | $6.75 |
| Resistance Level | $25.99 | N/A |
| Average True Range (ATR) | 1.20 | 1.02 |
| MACD | 0.18 | 0.30 |
| Stochastic Oscillator | 80.75 | 85.22 |
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.